Amifostine
- Generic Name
- Amifostine
- Brand Names
- Ethyol
- Drug Type
- Small Molecule
- Chemical Formula
- C5H15N2O3PS
- CAS Number
- 20537-88-6
- Unique Ingredient Identifier
- ILA426L95O
- Background
A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
- Indication
For reduction in the cumulative renal toxicity in patients with ovarian cancer (using cisplatin) and moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.
- Associated Conditions
- Dry Mouth, Nephrotoxicity, Prophylaxis of Radiation proctitis
- Associated Therapies
- -
High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 2
- Registration Number
- NCT05167370
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-11
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT03702985
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy
- First Posted Date
- 2013-11-29
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT01998529
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Phase II Study of Amifostine for the Prevention of Acute Radiation-Induced Rectal Toxicity
- First Posted Date
- 2012-04-26
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT01586117
- Locations
- 🇨🇳
Radiation Oncology Depratment, Cancer Hospital, CAMS, Beijing, Beijing, China
A Study of Amifostine for Prevention of Facial Numbness in Radiosurgery Treatment of Trigeminal Neuralgia
- Conditions
- Interventions
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 17
- Registration Number
- NCT01364259
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Sun Pharmaceutical Industries Limited
- Registration Number
- NCT01288625
A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 4
- Registration Number
- NCT00601198
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
- First Posted Date
- 2007-12-11
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 141
- Registration Number
- NCT00571298
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment
- Conditions
- Interventions
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00409331
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 48
- Registration Number
- NCT00318890
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.